International Agency for Research on Cancer (IARC), France Dr Maimuna Mendy (MM) Cancer, virology, biomarkers, proteomics Institute National de la Sante et de la Recherché Medicale (INSERM), France Prof Fabien Zoulim Dr Isabelle Chemin (IC) Infectious diseases, HBV virology Xeptagen Inc. Italy Dr Giorgio Fassina Diagnostic development, biomarkers MRC Gambia, Gambia Prof. Umberto D’Alesssandro (UDA) Clinical studies Le Dantec Hospital, Senegal Prof Soulemayne Mboup (SMB) Clinical studies Royal Victoria Teaching Hospital Dr Ignatius Baldeh (IB) Clinical studies Jos University Teaching Hospital (JUTH), Jos, Nigeria Prof Edith Okeke (EO) Clinical studies The project has been conducted within 7 workpackages (WP) summarized in Table 2: Table : PROLIFICA Workpackages Workpackage Lead unit/person Description WP1 Imperial College (MT) Coordination & management WP2 HCC case study Imperial College (MM) HCC control study dataset WP3 Anti- viral treatment cohort (WATCH) study Imperial College (MT), MRC (UDA) and Senegal (SMB) Treatment study WP4 Biomarker discovery and mechanistic investigations through proteomics Imperial College (STR) IARC (MM) Novel markers for liver cancer validation WP5 Development of metabonomic markers for the diagnosis of HCC Imperial College (STR) IARC (MM) Confirmed list of biomarkers WP6 INSERM, Lyon, France (IC) HBV molecular and serodiagnostics WP7 All partners Capacity building As lead Partner, the main role of Imperial College has been to act as the overall administrative co-ordinator of the project to ensure efficient collaboration, exchange of information and knowledge and fulfilment of ethical, regulatory and bio-safety rules. In addition, Imperial monitors the progress of the project, anticipating possible hurdles and working with the partners to find solutions. Specifically this includes detailing the overall work programme and budget, co-ordinating and monitoring scientific and financial reports, collecting and compiling results and organising project meetings.
5. Use and Dissemination of Foreground Section A: Dissemination Measures A1: List of scientific publications No Title Main author Title of the periodical Number, date or frequency Publisher Place of publication Year Pages Permanent identifiers Open Access 1 Screen and treat as an intervention programme for hepatitis B virus infection in sub-Saharan Africa: the PROLIFICA experience in The Gambia. Lemoine, M Thursz, M Lancet GH Under revision 2016 yes 2 Cost-Effectiveness of screening and treatment for Chronic Hepatitis B in The Gambia Nayagam, S Thursz, M Lancet GH Under revision 2016 yes 3 What is required for the global control and elimination of Hepatitis B incidence and mortality? Nayagam, S Hallet, T Lancet ID Under revision 2016 yes 4 Field battle against hepatitis B infection and HCC in Africa Lemoine, M Thursz, M Hepatology Under revision 2016 No 5 Diagnostic accuracy of the transpeptidase to platelet ratio (GPR) using transient elastography as a reference. Lemoine, M Y Gut Feb 2016 Epub ahead of print doi: No 6 Mother-to-child transmission of hepatitis B in sub-Saharan Africa Y Lemoine, M Lancet ID Jan 2016 19-20 doi: Yes 7 Hepatitis E virus infection and Alim Phar Feb;43(3) 2016 doi: No
hepatitis B and healthy controls. 24 The association between maternal Hepatitis E Antigen status as a proxy for perinatal transmission and the risk of Hepatitis e antigenemia in Gambian children Y Mendy, M BMC Public Health May 2014 doi: No 25 How long does one need to fast before a Fibroscan examination? Lemoine, M Aliment Pharmacol Ther. March 2014 541-2 doi: No 26 Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. Lemoine, M Liv Intern Jan 2014 12-15 doi: No 27 Viral hepatitis and the global burden, a need to regroup Cooke, G, J Viral Hep Sept 20(9) 2013 600-1 doi: No 28 Viral hepatitis in resource-limited countries and access to antiviral therapies : current and future challenges. Lemoine, M Thursz, M Fut Virol Apr 8(4) 2013 Yes 29 Protein Profiling in Hepatocellular Carcinoma by Label-Free Quantitative Proteomics in Two West African Populations Fye, HKS Mendy, ME PLoS One Jul 30;8(7) 2013 doi: Yes 30 Global eradication of hepatitis or fallacy? Thursz M, Lemoine, M Nat Rev Hepatology. 2012 492-4 doi: No 31 Lemoine, M J Public Health Policy. Nov 33(4): 2012 430-8 doi: No
A2: List of dissemination activities No Type of activity Main leader Title Place Type of audience Size of audience Countries Addressed 1 Meeting/education Thursz, M Hepatitis B in countries 12 Apr 2016 EASL Barcelona Physicians and NGO (MSF & MDM) 70 Gambia 2 Scientific meeting Lemoine HBV mother-to-child transmission in Africa Feb 2016 Paris Clinicans and researchers 20 Gambia/Senegal 3 Presentation of the PROLIFICA results Sow, A AfraVIH Apr 2016 Brussels Physicians, scientists, nurses and civil society mainly from Africa and France 5000 Senegal 4 Meeting, education and round table Lemoine, M “Rencontres Nord/Sud” Management of HBV infection in sub-Saharan Africa 22 Dec 2015 Paris Physicians, nurses and NGO from Europe and West Africa 50 Senegal, Gambia 5 Presentation of the PROLIFICA results Njie, R Thursz, M EASL Monothematic Conference: "Liver Disease in Resource Limited Settings". 29 Apr 2015 Bucharest Physicians, nurses and NGO from Europe and West Africa 200 Gambia 6 HBV-related HCC in Africa Gosh, S Chemin, I EASL Monothematic Conference: "Liver Disease in Resource Limited Settings". 29 Apr 2015 Bucharest Physicians, nurses and NGO from Europe and 200 Gambia
West Africa 7 Virological profiles of hepatitis b virus african patients treated with tenofovir Njai, H EASL Apr 2014 London Physicians, nurses and NGO from Europe and West Africa 10000 Gambia Presentation of the PROLIFICA results Njai, H Performance of two rapid tests of hepatitis b surface antigen for screening hepatitis b virus (HBV) infection in the rural communities of the Gambia Apr 2014 London Physicians, nurses and NGO from Europe and West Africa 10000 Gambia 6 Presentation of the PROLIFICA results Shimakawa, Y community-based screening for HBV infection in the Gambia, west Africa: prevalence of infection and factors affecting the screening attendance Apr 2013 (EASL) Physicians, nurses and NGO from Europe and West Africa 10000 Gambia 6 Presentation of the PROLIFICA results Lemoine, M Rural and urban community-based hepatitis b screening in the Gambia: assessment of liver disease reveals a significant proportion of eligible patients for antiviral therapy Apr 2013 (EASL) Physicians, nurses and NGO from Europe and West Africa 10000 Gambia 7 Presentation of the PROLIFICA results Lemoine, M Screen & treat intervention in the Gambia Dec 2013 London liver group from London 50 Gambia 8 9
Section B: B1: List of applications for patents, trademarks and registered designs Type of IP rights Confidential (yes/No) Foreseen embargo date Application reference Subject or title of application Applicant B2: Type of exploitable foreground Description of exploitable foreground Confidential (yes/No) Foreseen embago date Exploitable products or measures Sector of application Timetable, commercial or any other use Patents or other IPR exploitation Owner & other beneficiary involved